248 related articles for article (PubMed ID: 10766157)
1. p53 Antibodies in the sera of patients with various types of cancer: a review.
Soussi T
Cancer Res; 2000 Apr; 60(7):1777-88. PubMed ID: 10766157
[TBL] [Abstract][Full Text] [Related]
2. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.
Katchman BA; Barderas R; Alam R; Chowell D; Field MS; Esserman LJ; Wallstrom G; LaBaer J; Cramer DW; Hollingsworth MA; Anderson KS
Proteomics Clin Appl; 2016 Jul; 10(7):720-31. PubMed ID: 27121307
[TBL] [Abstract][Full Text] [Related]
3. Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53.
Salvioli S; Capri M; Bucci L; Lanni C; Racchi M; Uberti D; Memo M; Mari D; Govoni S; Franceschi C
Cancer Immunol Immunother; 2009 Dec; 58(12):1909-17. PubMed ID: 19139887
[TBL] [Abstract][Full Text] [Related]
4. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis.
Koziol JA; Zhang JY; Casiano CA; Peng XX; Shi FD; Feng AC; Chan EK; Tan EM
Clin Cancer Res; 2003 Nov; 9(14):5120-6. PubMed ID: 14613989
[TBL] [Abstract][Full Text] [Related]
5. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.
Oshima Y; Shimada H; Yajima S; Nanami T; Matsushita K; Nomura F; Kainuma O; Takiguchi N; Soda H; Ueda T; Iizasa T; Yamamoto N; Yamamoto H; Nagata M; Yokoi S; Tagawa M; Ohtsuka S; Kuwajima A; Murakami A; Kaneko H
J Gastroenterol; 2016 Jan; 51(1):30-4. PubMed ID: 25906289
[TBL] [Abstract][Full Text] [Related]
6. The sentinel within: exploiting the immune system for cancer biomarkers.
Anderson KS; LaBaer J
J Proteome Res; 2005; 4(4):1123-33. PubMed ID: 16083262
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens.
Zhang JY; Casiano CA; Peng XX; Koziol JA; Chan EK; Tan EM
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):136-43. PubMed ID: 12582023
[TBL] [Abstract][Full Text] [Related]
8. Status quo of p53 in the treatment of tumors.
Guan YS; He Q; Zou Q
Anticancer Drugs; 2016 Oct; 27(9):811-8. PubMed ID: 27384591
[TBL] [Abstract][Full Text] [Related]
9. Tumour-reactive plasma cells in antitumour immunity: current insights and future prospects.
Chen P; Chu Y; Liu R
Immunother Adv; 2024; 4(1):ltae003. PubMed ID: 38736973
[TBL] [Abstract][Full Text] [Related]
10. DNA-delivered monoclonal antibodies targeting the p53 R175H mutant epitope inhibit tumor development in mice.
Chai D; Wang X; Neeli P; Zhou S; Yu X; Sabapathy K; Li Y
Genes Dis; 2024 Jul; 11(4):100994. PubMed ID: 38560504
[TBL] [Abstract][Full Text] [Related]
11. A machine learning and directed network optimization approach to uncover
Triantafyllidis CP; Barberis A; Hartley F; Cuervo AM; Gjerga E; Charlton P; van Bijsterveldt L; Rodriguez JS; Buffa FM
iScience; 2023 Dec; 26(12):108291. PubMed ID: 38047081
[TBL] [Abstract][Full Text] [Related]
12. Redefining serological diagnostics with immunoaffinity proteomics.
Walter J; Eludin Z; Drabovich AP
Clin Proteomics; 2023 Oct; 20(1):42. PubMed ID: 37821808
[TBL] [Abstract][Full Text] [Related]
13. A Luminex Approach to Develop an Anti-Tumor-Associated Antigen Autoantibody Panel for the Detection of Prostate Cancer in Racially/Ethnically Diverse Populations.
Qiu C; Wang X; Batson SA; Wang B; Casiano CA; Francia G; Zhang JY
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627091
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
Heinzl N; Maritschnegg E; Koziel K; Schilhart-Wallisch C; Heinze G; Yang WL; Bast RC; Sehouli J; Braicu EI; Vergote I; Van Gorp T; Mahner S; Paspalj V; Grimm C; Obermayr E; Schuster E; Holzer B; Rousseau F; Schymkowitz J; Concin N; Zeillinger R
Oncogene; 2023 Aug; 42(33):2473-2484. PubMed ID: 37402882
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer autoantibodies - applications in diagnosis, prognosis, monitoring disease progression and immunotherapy.
Jayakrishnan R; Schafer C; Tan SH
Am J Clin Exp Urol; 2023; 11(2):79-102. PubMed ID: 37168942
[TBL] [Abstract][Full Text] [Related]
16. The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer.
Zhao J; Wu Y; Yue Y; Chen M; Xu Y; Liu X; Liu X; Gao X; Wang H; Si X; Zhong W; Zhang X; Zhang L; Wang M
Thorac Cancer; 2023 Feb; 14(5):497-505. PubMed ID: 36594104
[TBL] [Abstract][Full Text] [Related]
17. Development of a salivary autoantibody biomarker panel for diagnosis of oral cavity squamous cell carcinoma.
Hsueh PC; Chang KP; Liu HP; Chiang WF; Chan XY; Hung CM; Chu LJ; Wu CC
Front Oncol; 2022; 12():968570. PubMed ID: 36387116
[TBL] [Abstract][Full Text] [Related]
18. Comparative Microbiomics Analysis of Antimicrobial Antibody Response between Patients with Lung Cancer and Control Subjects with Benign Pulmonary Nodules.
Shome M; Gao W; Engelbrektson A; Song L; Williams S; Murugan V; Park JG; Chung Y; LaBaer J; Qiu J
Cancer Epidemiol Biomarkers Prev; 2023 Apr; 32(4):496-504. PubMed ID: 36066883
[TBL] [Abstract][Full Text] [Related]
19. Editorial: Tumor-associated antigens and their autoantibodies, from discovering to clinical utilization.
Zhang J; Guo X; Jin B; Zhu Q
Front Oncol; 2022; 12():970623. PubMed ID: 35936692
[No Abstract] [Full Text] [Related]
20. Nano-Based Theranostic Platforms for Breast Cancer: A Review of Latest Advancements.
Arshad R; Kiani MH; Rahdar A; Sargazi S; Barani M; Shojaei S; Bilal M; Kumar D; Pandey S
Bioengineering (Basel); 2022 Jul; 9(7):. PubMed ID: 35877371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
